SGRY · NASDAQ · STOCK
Surgery Partners, Inc.
$15.02
52W $11.41 – $24.10
48/100
$1.96B
-21.7
1.94
Is SGRY Bullish or Bearish?
Mixed.
Innellis AI committee rates Surgery Partners, Inc. (SGRY) Watch with a composite score of 48/100
, based on 6 analysts with 33% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +12.27 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -7.73 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.2x is a discount to asset value — Value
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.94 means this name should amplify a favorable market regime — Macro
- News sentiment is positive (+0.30 across 10 articles, 14d) — News
Bear Case
- ROE of only -4.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
- Revenue declining -20.5% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.16) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
48/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.2x is a discount to asset value
− ROE of only -4.6% -- cheap may mean cheap for a reason
Growth Analyst
bearish
15
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -20.5% YoY -- this is not a growth story right now
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.16) amplifies downside in a stress scenario
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
67
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.30 across 10 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
42.3
Neutral
MACD Histogram
-0.082
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$14.95
Resistance
$15.16
Bollinger %B
0.15
Inside Bands
Price vs Moving Averages
EMA 9
$15.49
Below
EMA 21
$15.61
Below
EMA 50
$15.37
Below
EMA 200
$16.03
Below
Fundamental Analysis
Valuation
100
Profitability
1
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
-21.7×
P/B Ratio
1.16×
PEG Ratio
-0.55
Dividend Yield
0.00%
52W High
$24.10
52W Low
$11.41
Quality & Growth
ROE
-454.8%
ROA
-94.5%
Gross Margin
2137.1%
Operating Margin
1189.4%
Revenue Growth YoY
—
Debt / Equity
2.40
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -21.7 (inexpensive relative to a 15-40x range); Price-to-book of 1.2x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -4.5%; Return on assets of -0.9%; Net margin of -2.6%; Gross margin of 21.4%; Current ratio of 1.95 (healthy short-term liquidity); Debt-to-equity of 2.40; Free cash flow per share is positive (1.46); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full SGRY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →